Abstract
Academic-industry collaborations are increasingly recognized as a catalyst for pharmaceutical innovation. While such partnerships are broadly valued across disciplines, their relevance to drug discovery is particularly pronounced due to the field's interdisciplinary complexity, high cost, and inherent risk. Drawing on direct experience of academic-industry collaborations, we explore the benefits and challenges.